ClinicalTrials.gg
WithdrawnNCT02616315Updated Apr 8, 2016

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

A Phase 4 interventional study of Naltrexone HCl/Bupropion HCl Placebo and Naltrexone HCl/Bupropion HCl in Weight Regain Post Bariatric Surgery, sponsored by Takeda. Withdrawn at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-04-08.

Sponsored by Takeda · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effect of naltrexone hydrochloride(HCL) and bupropion hydrochloride extended release combination (NB) compared with placebo on weight loss in obese participants post bariatric surgery.

Read the detailed description

The drug being tested in this study is called naltrexone hydrochloride/bupropion hydrochloride (NB). NB is being tested to determine its effect on weight loss in obese participants post bariatric surgery.

The study will enroll approximately 60 participants. Participants will be randomly assigned to one of the two treatment groups-which will remain undisclosed to the participant and study doctor during the study (unless there is an urgent medical need):

  • Naltrexone HCl 32 mg/bupropion HCl 360 mg extended-release tablet
  • Placebo (dummy inactive pill) - this is a tablet that looks like the study drug but has no active ingredient

All participants will start on 1 tablet a day and will increase their dose by 1 tablet per week for 4 weeks to reach the optimal dose.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 59 weeks maximum. Participants will make multiple visits to the clinic, plus a final visit 4 weeks after last dose of study drug for a follow-up assessment.

02

Conditions studied

  • Weight Regain Post Bariatric Surgery

Keywords

  • Drug therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Is female or male and aged 18 to 65 years, inclusive.
  4. Is at least 2 years post Roux-en-Y Gastric Bypass (RYGB) procedure for treatment of severe obesity prior to screening.
  5. Has achieved an initial weight loss of ≥20% of their preoperative body weight, and has regained ≥10% of the total weight lost.
  6. Has a (BMI) (weight [kg]/[height {m}]\^2) ≥30 kg/m\^2.
  7. A female participant of who is sexually active with a nonsterilized male partner agrees to routinely use adequate from signing of informed consent throughout the duration of the study and for 12 weeks after the last dose of study drug.
  8. Is able to speak and read English.

Exclusion criteria

Exclusion Criteria:

  1. Has obesity of known endocrine origin (eg, untreated hypothyroidism, Cushing's syndrome) or of genetic origin.
  2. Is currently using other bupropion- or naltrexone-containing products or has a history of or allergies to naltrexone or bupropion.
  3. Has a history of cancer that has been in remission for \<5 years prior to screening. A history of basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin is allowed.
  4. Has a history of Type 1 or current type 2 diabetes mellitus (T2DM) diagnosis.
  5. Has had a myocardial infarction within 6 months prior to screening.
  6. Has a history of Class III or IV congestive heart failure, as per the functional classification.
  7. Has a history of angina pectoris Grade III or IV, as per the Canadian Cardiovascular Society grading scheme.
  8. Has a clinical history of strokes, including ischemic and hemorrhagic strokes.
  9. Has a history (within the last 20 years) of seizures, cranial trauma, active bulimia, anorexia nervosa, or other conditions that predispose the participant to seizures.
  10. Has, in the judgment of the investigator, any (ECG), laboratory, hematology, physical examination, medical history, or urinalysis finding that should prohibit participation in the study.
  11. Has uncontrolled hypertension defined as blood pressure (BP) ≥145/95 mm Hg at screening. BP will be measured on 2 separate occasions with an approximate 30-minute interval between measurements at the screening visit.
  12. Has a thyrotropin (thyroid stimulating hormone -TSH) value outside the normal range at the screening visit; unless there is a normal triiodothyronine (T3) value.
  13. Had initiation or alteration of dose of antihypertensive or lipid-lowering agents within 4 weeks prior to screening.
  14. Used prescribed or over-the-counter drugs intended for weight loss, or participated in a weight loss program other than standard of care for a post bariatric population, within 3 months prior to randomization.
  15. Has prior or planned surgical or device intervention for obesity except for the required RYGB Surgery.
  16. Has a history or current diagnosis of angle-closure glaucoma.
  17. Is experiencing post bariatric dumping syndrome that may impact the conduct or outcome of the study as determined by the investigator.
  18. Has moderate or severe renal impairment (end-stage renal disease) defined as estimated (eGFR) \<60 mL/min/1.73m\^2, using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI).
  19. Has a clinical history of hepatic impairment or current documented (AST) or alanine aminotransferase (ALT) >3 times the (ULN) at the screening visit.
  20. Has glycosylated () ≥6.5% at Screening Visit.
  21. Has current known infection with (HIV) or hepatitis (documentation of no detectable virus is required for participants with a past infection of or C).
  22. Is undergoing an abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs.
  23. Is a chronic user or has a positive screen for opioids.
  24. Has a hemoglobin of ≤10 g/100 mL at the screening visit.
  25. Has a history of serious psychiatric illness such as:

    • A Patient Health Questionnaire (PHQ)-9 score ≥10 at the screening visit.
    • Bipolar disorder.
    • Schizophrenia.
    • Severe personality disorder (eg, borderline or antisocial).
    • Major depressive disorder.
    • Recent (previous 6 months) suicide attempt.
    • Other psychosis.
  26. If female, the participant is pregnant or trying to become pregnant, currently breast-feeding, or of (including perimenopausal women who have had a menstrual period within 1 year) and not willing to practice from signing of throughout the duration of the study and for 12 weeks after the last dose of study drug.
  27. Has received any compound within 30 days prior to the first dose of study medication.
  28. Has received Contrave in a previous clinical study or as a therapeutic agent.
  29. Is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (eg, spouse, parent, child, sibling) or may consent under duress.
  30. Is required to take excluded medications.
  31. Participant is enrolled in any other interventional study at the time of Screening and during the study
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Placebo comparator
    Group A: Placebo

    Naltrexone hydrochloride (HCl)/bupropion hydrochloride (HCl) placebo-matching tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl/bupropion HCl placebo-matching tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).

    Drug: Naltrexone HCl/Bupropion HCl Placebo

  • Experimental
    Group B: Naltrexone HCl/Bupropion HCl

    Naltrexone HCl 8 mg/bupropion HCl 90 mg, tablet, orally, 1 tablet in the AM, daily, during Week 1, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 1 tablet in the AM and 1 in the PM, during Week 2, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 1 in the PM, during Week 3, followed by naltrexone HCl 8 mg/bupropion HCl 90 mg, tablets, orally, 2 tablets in the AM and 2 in the PM, in Week 4 through Week 49. Participants must be re-titrated if off treatment for ≥1 week (≥7 days).

    Drug: Naltrexone HCl/Bupropion HCl

Interventions

  • DrugNaltrexone HCl/Bupropion HCl Placebo

    Naltrexone/bupropion placebo-matching tablets

  • DrugNaltrexone HCl/Bupropion HCl

    Drug pages: Naltrexone · Bupropion

    Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets

06

What researchers measure

Primary outcomes

  1. Percent Change from Baseline in Body Weight at Week 26

    Time frame: Baseline and Week 26

Secondary outcomes

  1. Percent Change from Baseline in Body Weight at Week 52

    Time frame: Baseline and Week 52

  2. Percentage of Participants Achieving a Loss of at Least 2%, 5%, or 10% of Baseline Body Weight at Weeks 26 and 52

    Time frame: Baseline and Weeks 26 and 52

  3. Changes from Baseline on Obesity-Associated Cardiovascular Risk Factors at Weeks 26 and 52

    Obesity-associated cardiovascular risk factors, including serum triglycerides, high density lipoprotein (HDL), and low density lipoprotein (LDL) cholesterol, and waist circumference.

    Time frame: Baseline and Weeks 26 and 52

  4. Change from Baseline in Fasting Glucose Levels at Weeks 26 and 52

    Time frame: Baseline and Weeks 26 and 52

  5. Change from Baseline in and Glycosylated Hemoglobin (HbA1c) Levels at Weeks 26 and 52

    Time frame: Baseline and Weeks 26 and 52

  6. Change from Baseline in Vital Signs at Weeks 26 and 52

    Vital signs include systolic and diastolic blood pressure \[BP\] and heart rate.

    Time frame: Baseline and Weeks 26 and 52

  7. Change from Baseline in Quality of Life as Measured by the Impact of Weight on Quality of Life Questionnaire - Lite Version (IWQOL-Lite) at Weeks 26 and 52

    The IWQOL-Lite, is a validated 31-item, self -reported, obesity-specific measure of health-related quality of life that consists of a total score and scores on each of 5 scales (physical function, self-esteem, sexual life, public distress, and work) that exhibits strong psychometric properties. Participants rate items within the scales as: 5=always true, 4=usually true, 3=sometimes true, 2=rarely true, or 1=never true. Scale scores are obtained by adding item scores, and the total score is obtained by adding scale scores. Higher scores indicate poorer quality of life.

    Time frame: Baseline and Weeks 26 and 52

07

Study locations

2 sites
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2016, a primary completion of Oct 2017 and a completion of Dec 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 24, 2015
First posted
Nov 26, 2015
Start
Feb 2016
Primary completionEst.
Oct 2017
CompletionEst.
Dec 2017
Last update
Apr 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02616315
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Nov 26, 2015
Start date
Feb 2016
Primary completion
Oct 2017 (estimated)
Completion
Dec 2017 (estimated)
Last update
Apr 8, 2016

Study contacts

Medical Director US Medical Affairs
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Naltrexone · Bupropion

Start the discussion